December 20, 2021 Press release - Non-regulatory Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
December 13, 2021 Press release - Non-regulatory Targovax to present at DNB’s 12[th] Nordic Healthcare Conference
November 18, 2021 Press release - Non-regulatory Targovax invites to webcast presentation in Norwegian
November 9, 2021 Press release - Non-regulatory Targovax announces two posters at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 27, 2021 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s third quarter 2021 results, Thursday 4 November
October 22, 2021 Press release - Non-regulatory Targovax invites to webcast presentation on Xtrainvestor
October 6, 2021 Press release - Non-regulatory Targovax ASA: Two abstracts accepted at the SITC Congress
September 30, 2021 Press release - Non-regulatory Targovax ASA appoints Ola Melin as Head of Manufacturing
September 24, 2021 Press release - Non-regulatory Targovax granted European Patent for ONCOS-102 in combination with chemotherapy
September 16, 2021 Press release - Non-regulatory Targovax ASA: Poster at European Society for Medical Oncology (ESMO)
August 27, 2021 Press release - Non-regulatory Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress
August 16, 2021 Press release - Non-regulatory Targovax to present at upcoming scientific conferences
May 21, 2021 Press release - Non-regulatory Targovax to present at upcoming investor and scientific conferences
March 9, 2021 Press release - Non-regulatory Targovax granted US Patent for ONCOS-102 in combination with checkpoint inhibitors
March 8, 2021 Press release - Non-regulatory Targovax to present and attend at upcoming investor and scientific conferences
February 24, 2021 Press release - Non-regulatory Targovax: Proposal for Remuneration Guidelines for Board and Executive Management
February 23, 2021 Press release - Non-regulatory Continued survival benefit in Targovax’s ONCOS-102 trial in mesothelioma at the 21-month follow-up
February 18, 2021 Press release - Non-regulatory Reminder: Invitation to Targovax’s Capital Markets Day 18 February 2021
February 15, 2021 Press release - Non-regulatory Targovax receives Fast-Track designation for ONCOS-102
February 11, 2021 Press release - Non-regulatory Agenda for Targovax’s Capital Markets Day 18 February 2021
February 10, 2021 Press release - Non-regulatory Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
February 9, 2021 Press release - Non-regulatory SOTIO has stopped collaboration trial with the dendritic cell vaccine DCVAC in combination with ONCOS-102
January 11, 2021 Press release - Non-regulatory Targovax to present at the H.C. Wainwright Virtual BioConnect 2021 Conference
January 6, 2021 Press release - Non-regulatory Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore